StockData
Celldex Therapeutics, Inc. logo

Celldex Therapeutics, Inc. (CLDX) stock

CLDXNasdaqIn Vitro & In Vivo Diagnostic SubstancesFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 7/30
$28.04−0.55 (-1.92%)

Close on Nov 17, 2026Market cap $2.20BP/E –Yield –

Celldex Therapeutics operating cash flow

Operating cash flow is the cash the business generates from its day-to-day operations.

Celldex Therapeutics's operating cash flow for the twelve months ending Jun 30, 2026 was -$235.57M. For fiscal 2025 it was -$210.95M. The highest annual figure on record is -$29.87M in fiscal 2009.

Annual operating cash flow

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$210.95M–
FY2024Dec 31, 2024-$157.78M–
FY2023Dec 31, 2023-$107.29M–
FY2022Dec 31, 2022-$103.73M–
FY2021Dec 31, 2021-$60.91M–
FY2020Dec 31, 2020-$40.40M–
FY2019Dec 31, 2019-$46.42M–
FY2018Dec 31, 2018-$75.24M–
FY2017Dec 31, 2017-$99.93M–
FY2016Dec 31, 2016-$113.04M–
FY2015Dec 31, 2015-$98.89M–
FY2014Dec 31, 2014-$101.54M–
FY2013Dec 31, 2013-$67.67M–
FY2012Dec 31, 2012-$49.78M–
FY2011Dec 31, 2011-$35.66M–
FY2010Dec 31, 2010-$30.37M–
FY2009Dec 31, 2009-$29.87M–

Quarterly operating cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$57.41M–
Q1 FY2026Mar 31, 2026-$65.59M–
Q4 FY2025Dec 31, 2025-$63.94M–
Q3 FY2025Sep 30, 2025-$48.63M–
Q2 FY2025Jun 30, 2025-$44.01M–
Q1 FY2025Mar 31, 2025-$54.37M–
Q4 FY2024Dec 31, 2024-$32.48M–
Q3 FY2024Sep 30, 2024-$55.34M–
Q2 FY2024Jun 30, 2024-$29.33M–
Q1 FY2024Mar 31, 2024-$40.64M–
Q4 FY2023Dec 31, 2023-$32.53M–
Q3 FY2023Sep 30, 2023-$18.99M–
Q2 FY2023Jun 30, 2023-$27.20M–
Q1 FY2023Mar 31, 2023-$28.57M–
Q4 FY2022Dec 31, 2022-$21.76M–
Q3 FY2022Sep 30, 2022-$35.19M–
Q2 FY2022Jun 30, 2022-$22.24M–
Q1 FY2022Mar 31, 2022-$24.53M–
Q4 FY2021Dec 31, 2021-$14.52M–
Q3 FY2021Sep 30, 2021-$16.37M–
Q2 FY2021Jun 30, 2021-$11.93M–
Q1 FY2021Mar 31, 2021-$18.08M–
Q4 FY2020Dec 31, 2020-$5.21M–
Q3 FY2020Sep 30, 2020-$11.86M–
Q2 FY2020Jun 30, 2020-$11.22M–
Q1 FY2020Mar 31, 2020-$12.11M–
Q4 FY2019Dec 31, 2019-$11.00M–
Q3 FY2019Sep 30, 2019-$11.14M–
Q2 FY2019Jun 30, 2019-$11.04M–
Q1 FY2019Mar 31, 2019-$13.23M–
Q4 FY2018Dec 31, 2018-$15.43M–
Q3 FY2018Sep 30, 2018-$14.39M–
Q2 FY2018Jun 30, 2018-$17.40M–
Q1 FY2018Mar 31, 2018-$28.02M–
Q4 FY2017Dec 31, 2017-$19.52M–
Q3 FY2017Sep 30, 2017-$24.36M–
Q2 FY2017Jun 30, 2017-$20.79M–
Q1 FY2017Mar 31, 2017-$35.26M–
Q4 FY2016Dec 31, 2016-$20.35M–
Q3 FY2016Sep 30, 2016-$23.96M–

More Celldex Therapeutics figures

See a number that looks wrong?